Anti-hypertensive Drugs Market Trends
The global anti-hypertensive drugs market size accounted for $22,557 million in 2018, and is expected to reach $28,797 million by 2026, registering a CAGR of 3.1% from 2019 to 2026. The factor that contribute toward antihypertensive drugs market growth of the global antihypertensive drugs market include surge in incidence of hypertension across the globe. Furthermore, rise in awareness related to complications associated with hypertension is a major factor that fuels the growth of the market. Moreover, increase in geriatric population and sedentary lifestyle boost the growth of the market. However, recent patent expirations are anticipated to hinder the growth of the anti-hypertensive drugs market. Conversely, rise in research related to antihypertensive drugs is expected to offer lucrative opportunities during the forecast period.
Market Introduction and Definition
Hypertension is defined as a long-term medical condition that is marked by high pressure of blood in the arteries, which is persistently elevated. Antihypertensive are used for treatment of patients suffering from high blood pressure-also known as hypertension. Hypertension is a major disorder accompanied with serious complications such as heart attack, heart failure, and dementia. Therefore, hypertension requires early diagnosis and treatment. Some of the drugs used for the treatment of hypertension include diuretics, ACE inhibitors, and vasodilators.
Market Segmentation
The global anti-hypertensive drugs market size is studied on the basis of therapeutic class, distribution channel, and region to provide a detailed assessment of the market. Depending on therapeutic class, the market is divided into diuretics, ACE inhibitors, calcium channel blockers, vasodilators, beta-adrenergic blockers, and others. By distribution channel, it is categorized into retail pharmacy, hospital pharmacy, and e-commerce. Region wise, the anti-hypertensive drugs market growth is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
Segment Review
According to therapeutic class, calcium channel blockers occupied the largest anti-hypertensive drugs market share in 2018, owing to lesser side effects exhibited by these drugs as compared to the other type of antihypertensive drugs. However, the ACE inhibitors segment is anticipated to depict fastest growth during the forecast period, due to benefits offered such as positive impact on overall health and decrease in progression of kidney diseases.
By Drug Class
Calcium Channel Blockers segment holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.
By distribution channel, the hospitals segment occupied the largest share. This is attributable to rise in number of hospitals worldwide. Furthermore, antihypertensive drugs are prescription-based medications, which are mostly prescribed by the specialized healthcare professionals available in hospitals, thereby augmenting the growth of this segment. On the contrary, the e-commerce segment is expected to exhibit the highest growth rate during the forecast period, owing to surge in the use of internet across the globe.
By Distribution Channel
E-commerce Websites and Online Drug Stores is projected as one of the most lucrative segment.
Regional/Country Market Outlook
Region wise, North America garnered the major share of the anti-hypertensive drugs market in 2018, and is expected to continue this trend in the near future, attributable to easy availability of antihypertensive drugs. Moreover, surge in incidence of hypertension and rise in geriatric population significantly contribute toward the growth of the market in this region. However, Asia-Pacific is projected to register the highest growth during the forecast period, owing to surge in awareness related to the use of anti-hypertensive drugs. Furthermore, the constantly evolving life science industry drives the growth of the market in the developing economies such as India, China, and Malaysia.
By Region
Asia-Pacific region would exhibit the highest CAGR of 4.2% during 2019-2026.
Competitive Landscape
The global anti-hypertensive drugs market is highly competitive, and prominent players have adopted various strategies for garnering maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Boehringer Ingelheim GmbH, Merck KGaA, Johnson and Johnson, Bayer AG, Pfizer, Inc. Takeda Pharmaceutical Co., Ltd., AstraZeneca plc, Daiichi Sankyo Company, Sanofi S.A., and Novartis International AG.
Key Benefits for Stakeholders
- This report entails a detailed quantitative analysis along with the current global anti-hypertensive drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
- The anti-hypertensive drugs market forecast is studied from 2019 to 2026.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Antihypertensive Drugs Market Report Highlights
| Aspects | Details |
 By DRUG CLASS |
|
 By END USER |
|
 By Region |
|
 Key Market Players | Johnson & Johnson, Lupin, Daiichi Sankyo Company, Limited, AstraZeneca plc, Novartis AG., Merck & Co., Inc, SANOFI, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories), Pfizer Inc. |
Analyst Review
Antihypertensive drugs are used to treat high blood pressure. High blood pressure is a chronic condition, which is related to rise in pressure of blood in the arteries of the patient. Furthermore, the condition is accompanied with other severe and fatal conditions such as heart attack and dementia. This medical condition is treated by using drugs such as beta blockers, vasodilators, and calcium channel blockers.
The utilization of antihypertensives has witnessed a significant growth, owing to surge in incidence of hypertension worldwide. Furthermore, other factors such as rise in geriatric population, surge in awareness related to complication of hypertension, and sedentary lifestyle are the factors that fuel the growth of the market. However, expiration of patents is a major factor that hinders the growth of the market.
The total market value of antihypertensive drugs market is $22,556.50 million in 2018.
The forcast period for antihypertensive drugs market is 2019 to 2026
The market value of antihypertensive drugs market in 2019 is $23,256.30 million
The base year is 2018 in antihypertensive drugs market
Top companies such as, Boehringer Ingelheim International GmbH, Johnson & Johnson, Novartis AG., Merck & Co., Inc, and Daiichi Sankyo Company, Limited., held a high market position in 2018.
Calcium channel blockers segment is the most influencing segment growing in the antihypertensive drugss market
The key trend in the antihypertensive drugs market is the rise in prevalence of hypertension across the globe which drives the growth of the market.
Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 5.1%.
Loading Table Of Content...
